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ABSTRACT   
 
Twin pregnancy is a high-risk condition obstetricians have to deal with frequently in clinical 
practice and its incidence has risen dramatically over the last decades. Additionally, hypertensive 
disorders including preeclampsia (PE), are amongst the most common medical complications of 
pregnancy and a major cause of maternal and perinatal morbidity and mortality. While it is 
unquestionable that multiple pregnancy has an increased risk of PE, it is still unclear what other 
risk factors are significant in the development of PE in twins.  
The exact pathophysiology of PE is uncertain. Traditionally it was thought to be a condition of 
poor placentation, resulting in generalized vascular endothelial activation and vasospasm, with 
typical cardiovascular clinical manifestations. Recent published data support the hypothesis that 
an angiogenic/anti-angiogenic balance plays a causative role in endothelial cell injury. The impact 
of the maternal cardiac function in the development of PE has become more relevant in the last 
years.  
The early detection of pregnancies at high-risk of PE could improve the maternal and neonatal 
outcome by a more individualized patient surveillance and the timely institution of prophylactic 
measures. In singleton pregnancies, screening for PE in the first trimester using a combined 
approach has a high detection rate. In twin pregnancies data related to PE screening is limited and 
inconsistent. 
The objective of this thesis is to clarify some of the issues with regard to PE in twin pregnancy. We 
set out to determine the relative risk for total and preterm-PE in multiple pregnancy when 
compared with singletons. Additionally, the aim is to assess the effect of maternal characteristics 
and medical history in the prediction of PE in twin pregnancies. The final goal is to develop a 
screening model for PE in twins by a combination of maternal factors and biomarkers.  
The research developed consists of three prospective screening studies for PE, with a population 
of 2219 twin pregnancies. In the first study, we found that there is a hidden high risk of PE in twin 
pregnancies. Although, as classically described, the relative risk of total PE is about three times 
higher in twins, the risk of preterm-PE is nine times higher than in singleton pregnancies. In the 
second study, we evaluated the effect of maternal and pregnancy characteristics on the risk of PE.  
Screening for preterm PE using maternal factors has a very high detection rate (99-100%) but at 
the expense of an extremely high screening positive rate (97-99%). In the third study, we 
developed a model combining maternal characteristics with biophysical and biochemical markers 
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to screen for PE in twin pregnancies. The performance of the screening model for preterm PE was 
very good with a detection rate for PE before 32 weeks of 100%, at any cut-off used. Once again 
the screen positive rate was high: 25%, 65% and 75%, using a cut-off 1:10, 1:50 or 1:75, 
respectively. 
We believe that increasing the knowledge about PE in twin gestation may allow an improvement 
in patient’s surveillance, the implementation of an effective screening method and the 
development of a preventive strategy.  
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RESUMO   
 
A gravidez gemelar é uma condição de alto risco, com a qual os obstetras têm que lidar 
frequentemente na prática clínica e cuja incidência tem vindo a aumentar drasticamente nas 
últimas décadas. Por outro lado, a patologia hipertensiva incluindo a pré-eclâmpsia (PE), é uma 
das complicações médicas mais comuns na gravidez, sendo uma importante causa de morbilidade 
e mortalidade materna e perinatal. Embora seja inquestionável que a gravidez múltipla tem um 
aumento do risco de PE, existem ainda dúvidas sobre quais são os outros factores de risco 
relevantes para PE na gravidez gemelar. 
A fisiopatologia exata da PE é desconhecida. Tradicionalmente é considerada uma condição 
resultante de uma placentação anómala, que causa uma ativação endotelial vascular generalizada 
e vasoespasmo, com manifestações clínicas cardiovasculares específicas. Estudos mais recentes 
defendem a hipótese de que um equilíbrio angiogênico/antiangiogênico desempenhe um papel 
causal na lesão das células endoteliais. O papel da função cardíaca materna no desenvolvimento 
da PE tornou-se mais pertinente nos últimos anos. 
A identificação precoce de gestações com elevado risco de PE poderá melhorar o desfecho 
materno e neonatal, através de uma vigilância mais individualizada e da instituição atempada de 
medidas profiláticas. Nas gravidezes únicas, a utilização no primeiro trimestre de um método de 
rastreio combinado para a PE tem uma elevada taxa de detecção. Em gravidezes gemelares, os 
dados sobre o rastreio da PE são limitados e inconsistentes.  
O objetivo desta tese é esclarecer alguns das dúvidas acerca da PE na gravidez múltipla. Em 
primeiro lugar pretendemos determinar o risco relativo para PE total e PE pré-termo em 
gestações gemelares quando comparadas com gestações únicas. Além disso, queremos avaliar o 
efeito das características maternas e da história clínica na predição de PE em gémeos. O objetivo 
final é desenvolver um modelo de rastreio para a PE na gravidez gemelar combinando fatores 
maternos, marcadores biofísicos e bioquímicos. 
A investigação  desenvolvida consiste em três estudos prospectivos de rastreio para PE, realizados 
em 2219 gravidezes gemelares. No primeiro estudo, constatou-se a existência de um elevado 
risco oculto de PE na gravidez gemelar. Embora, tal como classicamente descrito, o risco relativo 
de PE total seja cerca de três vezes superior nos gémeos, o risco de PE pré-termo é nove vezes 
maior do que em gestações únicas. No segundo estudo, avaliámos o efeito das características 
maternas e da história clínica no risco de PE. O rastreio da PE pré-termo, através de fatores 
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maternos, tem uma taxa de detecção muito elevada (99-100%), mas à custa de uma taxa 
extremamente alta de gravidezes com um rastreio positivo (97-99%). No terceiro estudo, 
desenvolvemos um modelo de rastreio para a PE nas gestações gemelares que combina as 
características maternas com marcadores biofísicos e bioquímicos. O desempenho do modelo de 
rastreio para a PE pré-termo foi notável, com uma taxa de detecção de PE antes de 32 semanas 
de 100%, em qualquer ponto de corte utilizado. Mais uma vez a percentagem de gravidezes com 
rastreio positivo foi alta: 25%, 65% e 75%, usando um ponto de corte 1:10, 1:50 ou 1:75, 
respectivamente. 
Acreditamos que aprofundar o conhecimento sobre PE na gravidez gemelar pode permitir uma 
melhoria na vigilância destas gravidezes, a implementação de um método de rastreio eficaz e o 
desenvolvimento de uma estratégia preventiva. 
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HISTORICAL PERSPECTIVE  
The occurrence of seizures in pregnancy and its association with a poor obstetric prognosis was 
described as early as in the 5th century, BC. (Chesley, 1984) Throughout the following centuries 
numerous narratives and reports of cases suggestive of eclampsia can be found in medical and 
midwifery books. Nevertheless, only in 1739 did the word eclampsia was used for the first time to 
describe an acute form of convulsion by opposition to a chronic form of seizures (epilepsy). The 
association of proteinuria with eclamptic seizures was described in 1840 by Rayer, and the presence 
of high blood pressure soon after. In 1894, Vinay reported that high blood pressure and proteinuria 
could occur in pregnant women without eclamptic seizures and he defined the term preeclampsia 
(PE). (Chesley, 1984) 
Nowadays preeclampsia is a global health problem of increasing significance and a leading cause of 
maternal and perinatal morbidity and mortality. (Duley, 2009; ACOG, 2013; Townsend et al., 2016)   
On the other hand, with the increase in maternal age and the expanding use of assisted reproductive 
technology (ART), obstetricians face a growing number of multiple pregnancies. Twin pregnancy is a 
high-risk condition that differs from singletons in terms of monitoring, complications and outcomes. 
(Ananth & Chauhan, 2012; Fletcher, 2015; Chasen & Chervenak, 2017) Overall, it constitutes 2-5% of 
all pregnancies and has an increased risk of almost every pregnancy complication, with PE being one 
of the most significant. (ACOG, 2016) 
DEFINITION 
Preeclampsia is a pregnancy-specific hypertensive disorder, progressive and multi-systemic. The 
aetiology and pathophysiology are not fully understood, leading to discrepancies in the description of 
the disease. There is no consensus amongst the major scientific societies in terms of definition, 
diagnostic criteria and guidelines. (ISSHP, 2001; SOMANZ, 2009; NCCWCH, 2010; ACOG, 2013) 
PE is characterized by the occurrence of a combination of symptoms and signs. Most definitions have 
a common base: the presence of hypertension and proteinuria in previously normotensive women, 
after 20 weeks of gestation.  
The most commonly used diagnostic criteria for PE are from the International Society for the Study of 
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Hypertension in Pregnancy (ISSHP): development of hypertension (blood pressure of 140/90 mmHg 
on two separate occasions four hours apart after 20 weeks of gestation) in previously normotensive 
women with the presence of proteinuria (300 mg or more in 24 hours or two readings of at least ++ 
on dipstick analysis of midstream or catheter urine specimens if no 24-hour collection is available). 
(ISSHP, 2001) 
In 2014, the definition was adjusted by the ISSPH, further to which the clinical diagnosis of PE should 
be made in the presence of de novo hypertension after 20 weeks of gestation and new onset of one 
or more of the following criteria (table 1). (ISSHP, 2014) 
Table 1.1 - Revised definition of PE (Adapted from ISSHP, 2014).  
Hypertension developing after 20 weeks gestation and one or more of the following new onset conditions:  
Proteinuria 
Other maternal organ dysfunction: 
 renal insufficiency (creatinine  90 mol/L)  
 liver involvement (elevated transaminases and/or severe right upper quadrant or epigastric pain) 
 neurological involvement (hyperreflexia accompanied by clonus, severe headaches accompanied by 
hyperreflexia, persistent visual scotomata, eclampsia, altered mental status, blindness, stroke) 
 haematological complications (thrombocytopenia, haemolysis, Disseminated Intravascular Coagulation) 
Uteroplacental dysfunction - fetal growth restriction 
The above clinical manifestations result from mild to severe microangiopathy of the respective organs 
(kidney, liver, brain and placenta) and should resolve completely within 12 weeks postpartum. 
(Tranquilli et al, 2014; ISSHP, 2014) 
For the purposes of this thesis, we chose to use the ISSHP definition as it represents a consensus view 
of an appropriate definition for research. (ISSHP, 2001) 
In terms of gestational age, PE can be classified as early-onset, when the diagnosis is at or before 34 
weeks gestation, and as preterm or term according to the need for iatrogenic delivery before or after 
37 weeks of gestation, respectively. (Von Dadelszen  et al, 2003; August & Sibai, 2017) 
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INCIDENCE 
Hypertensive disorders are amongst the most common medical complications of pregnancy with a 
described incidence varying from 5-10%. (Sibai, 2003)  
Gestational hypertension (GH) occurs approximately in 8-10% of the pregnancies and it is associated 
with a small increase in the risk of maternal, fetal or neonatal complications. (Walker, 2000)  
PE complicates 4-5% of pregnancies worldwide and according to different studies its incidence has 
increased by 25% in the past two decades. (Hutcheon et al., 2011; Abalos et al., 2013; Ananth et al., 
2013; Lisonkova et al., 2014) The incidence rate significantly varies according to the studied 
population due to social, economic and racial differences. Consequently, while in developing 
countries PE or eclampsia affects around 5% of pregnancies, in some African countries the incidence 
may be as high as 20%. (WHO, 1988; WHO, 2003)  
PE is a major cause of maternal and perinatal mortality and morbidity. Its severity ranges from a mild 
disorder with transient hypertension and proteinuria, to a life threatening illness with convulsions 
(eclampsia) or HELLP (Hemolysis, Elevated liver enzymes and Low platelet) syndrome. PE is estimated 
to be responsible for an average of 50000 maternal deaths every year, worldwide. Although the 
global burden of mortality attributed to PE is 12%, in some countries in Africa and South America this 
number can be as high as 35-40%. This emphasizes the disparity in incidence and severity in the 
different parts of the globe. (Walker, 2000; López-Jaramillo et al., 2001) 
PREECLAMPSIA IN TWIN PREGNANCIES  
Women with multiple gestations have an increased risk of hypertensive disorders. The reported 
incidence ranges from 13-36%. (McMullan, 1984; Krotz et al., 2002; Taguchi et al., 2014; ACOG, 2016)  
This fact was first noticed by Hinselmann on the 18th century. Of the 7748 cases of eclampsia 
recorded in his work, 6.4% were in twin pregnancies, a rate 5.8 times higher than in singletons. 
(Chesley, 1984) During the last 20 years, numerous studies were published comparing single and 
multiple pregnancy in terms of rate of gestational hypertension, preeclampsia and eclampsia. 
According to those reports, the relative risk of gestational hypertension is 1.2 to 2.7, for PE is 2.8 to 
4.4 and for eclampsia 3.4 to 5.1, when comparing twin to singleton gestations. (Sibai et al., 2000; 
Krotz et al., 2002; Duckitt, 2005) 
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RISK FACTORS IN TWIN PREGNANCIES 
Multiple factors have been identified as potentially increasing the incidence and severity of 
hypertensive disorders in singleton pregnancies. The most important ones are nulliparity, advanced 
maternal age (AMA), black race, obesity, ART, gestational diabetes and antiphospholipid antibodies.  
(August & Sibai, 2017) 
It is undeniable that multiple pregnancy is an important risk factor for gestational hypertensive 
disorders. Although it can be presumed that the risk factors for PE in twin pregnancies are the same 
as those for singleton pregnancies, due to the different maternal and pregnancy characteristics of 
twin pregnancies, this hypothesis is unproven. Data are limited, contradictory and most of the 
published studies have important bias, limiting the strength of the evidence available. (Fox et al., 
2014a) 
Parity  
Similar to singleton pregnancies, parity appears to have a significant impact in the development of PE 
in multiple gestations. According to the literature, nulliparity increases the relative risk of PE 
approximately 3 times (1.6-5.2) in twin pregnancy. Additionally, the combination of nulliparity with a 
twin pregnancy increases the risk of PE around 14 times when compared to a multiparous with a 
singleton pregnancy. (Coonrod et al., 1995 ; Krotz et al., 2002 ; Fox et al., 2014a; Taguchi et al., 2014)  
Age  
When analysing maternal age, the risk of PE has a U-type distribution, with the lowest between 25 
and 29 years and the highest in the group over 40 years. Young mothers (less than 17 years of age) 
with twin pregnancies have a relative risk 1.5 times higher for developing PE compared to those aged 
17 to 25, and at an even higher risk compared to those older than 25 years. (Krotz et al., 2002)  
Race  
In twin pregnancies, race seems to play a less important role than in singletons, with black mothers 
having only a 1.8 times higher risk of PE than white mothers. (Krotz et al., 2002) 
Pregestational Body Mass Index  
Some studies showed that a higher pregestational Body Mass Index (BMI), especially a BMI superior 
to 30.0 kg/m2, significantly and independently increases the risk of PE in twins. (Lucovnik et al., 2012; 
Fox et al., 2014a)  
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Previous history of hypertensive disorder in pregnancy 
As in singleton pregnancies, a past history of preeclampsia increases the risk of developing PE, when 
compared with women without this background. (Suzuki & Igarashi, 2009; Taguchi et al., 2014) 
Zygosity 
There are numerous studies investigating the incidence of PE in relation to zygosity in twin 
pregnancies. The results are conflicting and the incidence of PE in monozygotic twins has been 
reported as higher, similar or lower compared to dizygotic twin pregnancies. (Campbell, 1977; 
Savvidou et al., 2001) These contradictory results may be due to the changing definitions of PE over 
time, as well as to the determination of zygosity. The only accurate way to determine zygosity is 
analysing DNA markers, which can only be done prenatally by invasive testing. From a clinical point of 
view, the determination of zygosity is not easily available and it does not have the potential to be 
used as an element in screening large populations. (Sebire, 2002; Singh et al., 2014)  
Chorionicity 
Much more important than zygosity is chorionicity. Chorionicity can be reliably determined in the first 
trimester of pregnancy by ultrasonography and this information can be used prenatally to counsel 
these women. The association between PE and chorionicity is unclear and the existing data are 
inconsistent. There are studies showing a higher risk in dichorionic (DC) twins (Sparks et al., 2013; 
Sarno et al., 2014; Bartnik et al., 2016), others revealing a lower risk of PE (Campbell & Macgillivray, 
1999; Campbell & Templeton, 2004) and some concluding lack of association. (Savvidou et al., 2001; 
Suzuki & Igarashi, 2009) 
These incongruent findings can be explained by inconsistent diagnostic criteria for PE, small sample 
sizes and lack of adjusting the data to possible confounding factors. One important bias is the 
gestational age at delivery, as the incidence of PE could be influenced by the higher rate of preterm 
delivery in monochorionic (MC) twins. Another important confounder is maternal age: DC twins are 
more frequent in older mother. If corrections are not done, the data will be severally bias. More 
recent studies using multiple logistic regression revealed that chorionicity has no effect on the 
development of PE after adjusting for confounding factors like maternal age, race, parity and 
gestational age at delivery. (Fox et al., 2014a; Singh et al., 2014; Carter et al., 2015) 
INTRODUCTION 
26 
 
Assisted Reproductive Technology 
ART role in the incidence of PE in multiple gestations has been explored in several studies but with 
inconsistent and controversial findings. Some authors found an increased risk of PE in the ART group 
(Daniel et al., 2000; Erez et al., 2006; Chaveeva et al., 2011; Pourali et al., 2016) while others found no 
difference between the two groups. (Suzuki & Igarashi, 2009; Lučovnik et al., 2012; Moini et al., 2012; 
Anbazhagan, 2014; Geisler et al., 2014)  
Similar to what happens with chorionicity, these contrasting findings can be related to sample sizes 
and not taking in consideration possible confounding factors. When using a multiple logistic 
regression model the use of ART by itself seems to have no influence in the risk of PE. (Fan et al., 
2013; Fox et al., 2014a) Nevertheless, some particularities of the technique used such as egg 
donation, seem to increase the rate of PE. (Fox et al., 2014a) 
Other factors 
Different studies have examined the significance of other traditional risk factors for PE. Gestational 
diabetes, family history of hypertension, maternal smoking, income level and genetic factors 
apparently have little or no effect on the development of PE in twins. (Krotz et al., 2002; Lučovnik et 
al., 2012; Fox et al., 2014a; Taguchi et al., 2014)  
The latest studies support that the only risk factors independently associated with PE in twin 
pregnancy are pregestational high BMI, egg donation, previous history of hypertensive disorder in 
pregnancy and probably nulliparity. (Fox et al., 2014a; Taguchi et al., 2014) Additional studies are 
needed to confirm theses findings. 
PATHOPHYSIOLOGY  
The exact aetiology and pathogenesis of PE is largely unknown but it is likely to involve both maternal 
and placental factors. Abnormalities in the development of placental vasculature in early pregnancy 
may cause placental hypoxia and the release of factors leading to maternal endothelial dysfunction, 
causing hypertension and other manifestations of the disease. Considering there is no scientific 
evidence of a different pathogenesis of PE in twin pregnancy, it is logical to presume that the same 
mechanisms may be involved. (Karumanchi et al., 2017) 
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Figure 1.1 Pathogenesis of preeclampsia. (Power et al., 2011) (Reprinted with permission from 
Wolters Kluwer Health, Inc.) AT1-AAs: Angiotensin II Type I Receptor Activating Autoantibodies; NK cells: Natural Killer 
cells; sFlt1: soluble Fms-like tyrosine kinase-1; sEng: soluble Endoglin.  
Immunological factors  
The immune incompatibility theory supports that the immunological/genetic differences between 
mother and fetus contribute to the development of PE. This theory states that an immunologic event 
early in pregnancy activates a maladaptation of the maternal immune system to the fetal 
trophoblastic tissue. (Karumanchi et al., 2017) 
Various studies have proved the existence of increased levels of fetal nucleic acids and 
syncytiotrophoblast microparticles in maternal blood amongst women with PE. Others have studied 
immune mechanisms such as maternal natural killer cell interactions and cytotoxic T-cell responses as 
leading events to PE. If the immunological load is determinant in the development of PE, the 
INTRODUCTION 
28 
incidence of PE should be higher in dizygotic twins and similar in monozygotic twins and singleton 
pregnancies. Given most of the dichorionic twins are dizygotic it would be expected that the 
incidence of PE to be higher in DC compared to MC twins. The more recent studies have however 
demonstrated similar incidences in both types of twins, which does not support the immunological 
concept. (Maxwell et al., 2001 ; Savvidou et al., 2001 ; Sparks et al., 2013 ; Singh et al., 2014)  
Placentation  
One of the keys elements involved in PE is placentation. An impaired trophoblastic invasion of 
maternal spiral arteries can lead to high-pressure flow and damage of the placenta, resulting in 
placental hypoxia and release of factors leading to maternal endothelial dysfunction. The endothelial 
dysfunction is the main responsible factor for clinical manifestations like hypertension, proteinuria 
and end-organ damage. (Long & Oats, 1987; Moldenhauer et al., 2003; Rizzo et al., 2014; Ohkuchi et 
al., 2017)  
One possible explanation for the increased rate of PE amongst women with twin gestations is the 
placental mass hypothesis. Twins have a larger placental volume, which may cause an increased 
release of molecules with anti-angiogenic activity, like soluble fms-like tyrosine kinase-1 (sFlt-1) and 
soluble endoglin (sEng). However, some studies found no correlation between placental mass and 
circulation levels of anti-angiogenic factors, making the placental mass hypothesis unlikely. (Sparks et 
al., 2013; Fauple-Badger, 2015 ; Dröge et al., 2015 ; Bartnik et al., 2016)  
Another possible justification for the increased of PE amongst twin gestation is the existence of a less 
efficient placentation, related with the total implantation site area. In twins is much more likely that 
at least one placenta is implanted in a hostile part of the uterus, potential resulting in some degree of 
utero-placental compromise and chronic hypo-perfusion. It is undoubted that the anti-angiogenic 
factors have a vasoconstrictor role and induce placental ischemia/hypoxia, but it is still not clear 
whether placental hypoxia is the effect or the cause of increased anti-angiogenic factors release. 
(Sebire, 2002; Fauple-Badger, 2015)  
Angiogenic factors  
The angiogenic/angiostatic balance theory supports that there is a variation in the balance of 
angiogenic proteins, inflammatory cytokines and other immune-modulating molecules in pregnancies 
with PE. These factors are thought to cause maternal endothelial dysfunction and a systemic 
inflammatory reaction. (Sargent et al., 2003; Karumanchi et al., 2017) 
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Placental growth factor (PlGF) is part of the vascular endothelial growth factor (VEGF) family. It is a 
protein mainly expressed in the placenta and is considered to be an angiogenic factor. It appears to 
be involved in mediating increased endothelial vascular permeability cells and angiogenesis. (Power 
et al., 2011; Karumanchi et al., 2017) 
sFlt-1 is also protein produced by the syncytiotrophoblast but has an anti-angiogenic effect by 
inhibiting VEGF and PlGF activity. VEGF is important in maintaining endothelial function in fenestrated 
endothelium especially in the brain, liver and renal glomeruli. High levels of sFlt-1 have 
vasoconstrictor effects and, by interfering with VEGF function, cause endothelium dysfunction in 
main organs. (Karumanchi et al., 2017) 
sEng is produced by the placenta and is an anti-angiogenic protein that appears to be another 
important mediator of PE. It acts by inhibiting transforming growth factor (TGF) signalling in 
endothelial cells, causing increased vascular permeability and hypertension. (Karumanchi et al., 2017) 
Numerous studies in singletons showed an elevation in sFlt-1 and sEng, two anti-angiogenic proteins, 
previously to the clinical manifestation of PE. The circulating levels of PlGF decrease before the onset 
of PE and an increased of the sFlt-1/PlGF ratio has also been shown to precede the clinical symptoms 
of PE. (Ohkuchi et al., 2017)  
In twin pregnancy angiogenic proteins levels were found to be higher than in singletons throughout 
all the pregnancy. (Fauple-Badger, 2015) These findings support the hypothesis that the 
angiogenic/angiostatic balance plays a relevant role in endothelial cell injury, in multiple as in 
singleton pregnancies. Although the placenta is central to the process, it remains unclear what causes 
sFlt-1 to increase and PlGF to decrease in women with PE, but it probably points to the multifactorial 
aspect of this disease. (Fauple-Badger, 2015)   
Cardiovascular theory 
Despite the fundamental role of the cardiovascular system in PE, data about the interaction between 
the placenta and the maternal heart are still limited.  
It has been proposed that numerous cases of PE can be related to failure of the maternal heart 
muscle to remodel, especially in relation to diastolic blood pressure. Recent studies consistently show 
that women with placental failure and impaired left ventricle (LV) function were more likely to 
develop early-onset PE. These results originated the theory that the maternal cardiovascular response 
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to placental dysfunction may play an important role in the pathophysiology of PE. These cardiac 
changes may also play a part in the increased pre-disposition of women with PE to develop long-term 
cardiovascular disease. (Bellamy, 2007; Melchiorre et al., 2014; Osol & Bernstein, 2014)  
In twins pregnancy complicated by PE it is recognized that the maternal cardiac function does not 
undergo the physiological changes that are required for adaptation to pregnancy. As in singletons, a 
failure in maternal cardiac adaptation, demonstrated by a lower cardiac output and increased total 
vascular resistance, has been associated with an increased risk of PE. (Ghi et al., 2011)  
CLINICAL MANIFESTATIONS 
The clinical manifestations of PE appeared to be similar in singleton and twins. (August & Sibai, 2017) 
Table 1.2- Clinical manifestations of preeclampsia 
Symptoms          Signs         Laboratory findings 
Persistent and/or severe headache Raised in BP Proteinuria 
Visual abnormalities Peripheral edema  Elevated creatinine  
Right upper abdominal and/or epigastric pain    Generalized hyperreflexia  Decreased platelet count  
Nausea and/or vomiting Seizure Hemoconcentration  
Oliguria / Anuria  Hyperuricemia  
Altered mental status  Elevated transaminase levels  
 
However, hypertensive disorders in twin pregnancies tend to occur earlier and to be more severe. 
Preterm PE occurs 2.8 - 3.7 times more frequently than in singleton pregnancies. This results in a 
higher probability of complications, such as preterm delivery: 34.5% in twin gestation versus 6.3% in 
singletons. (Long & Oats, 1987; Sibai et al., 2000 ; Krotz et al., 2002 ; Yuan et al., 2016) Twin 
pregnancies also have an increased risk (about 3 times higher) of eclampsia than singletons. Abruptio 
placentae was found to be 8.2 times more frequent in twin pregnancies with PE when compared to 
singleton pregnancies and 5.4 times when compared to normotensive twin pregnancies. (Long & 
Oats, 1987; Krotz et al., 2002; Svirsky et al., 2013; Henry et al., 2013; Taguchi et al., 2014)  
The diagnosis and management of PE are similar to those in singleton pregnancies. (Chasen & 
Chervenak, 2017).  
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SCREENING 
The early detection of pregnancies at high-risk of developing PE may improve the maternal and 
neonatal outcome. The definition of a high-risk population would allow a more intensive and tailored 
patient surveillance and the institution of prophylactic measures to prevent PE. (Poon et al., 2009; 
Nicolaides, 2011; ACOG, 2015)  
In singleton pregnancies, screening for PE in the first trimester using prediction statistical models has 
a high detection rate. (Akolekar et al., 2011) When using a multifactor approach, combining maternal 
characteristics, mean arterial pressure (MAP), uterine artery pulsatility index (UtA-PI), pregnancy 
associated plasma protein-A (PAPP-A) and PlGF, the predicted detection rate for early PE is 93.4% for 
a 5% false-positive rate. (Akolekar et al., 2013)  
In twin pregnancies, PE screening data are scarce. The importance of identifying twin pregnancies at 
higher risk of developing PE is high because of the association with an increased risk of perinatal 
morbidity and both short and long-term maternal complications. Several studies assessed the 
potential impact of the factors traditionally used in screening for PE in singletons, in screening for PE 
in twin pregnancies. (Fox et al., 2014a; Rizzo et al., 2014; Fauple-Badger, 2015; Svirsky et al., 2016)  
Maternal characteristics 
The most relevant maternal characteristics determining the risk of PE in twin pregnancies are not the 
same of singleton pregnancies. As stated before, the most important risk factors associated with PE in 
twin pregnancy are pregestational high BMI, egg donation, previous history of hypertensive disorder 
in pregnancy and nulliparity. (Fox et al., 2014a; Fox et al., 2014b; Taguchi et al., 2014) 
Mean arterial pressure 
The studies evaluating the distribution of MAP values found that the MAP measures, in unaffected 
pregnancies, were similar in twin and singleton pregnancies. Additionally, in twins with PE the levels 
of MAP were elevated parallel to what happens in singletons with PE. Another important finding was 
that MAP measurements were unrelated to chorionicity. (Svirsky et al., 2014) It seems that if 
screening of PE in twins is to be implemented, the curve used to express MAP levels in Multiple of 
Median (MoMs) in singletons can be use in twin pregnancy.  (Svirsky et al., 2014) 
INTRODUCTION 
32 
Uterine artery pulsatility index 
Measurement of uterine artery pulsatility index may be useful in prediction of uteroplacental 
dysfunction in twin pregnancy. Several studies confirmed an association between increased uterine 
artery resistance from the first trimester of pregnancy and subsequent PE. (Yu et al., 2002; Geipel et 
al., 2002; Yu et al., 2008; Rizzo et al., 2014) 
Figure 1.2 a) Transabdominal technique to obtain uterine artery waveform. B) Pulsed wave signal of 
uterine artery blood flow. (Adapted from Preeclampsia screening, FMF). (Fetal Medicine Foundation, 
2018) 
Several authors suggest that routine assessment of the uteroplacental circulation by measuring the 
UtA-PI may be of benefit in the clinical management of twin pregnancies by identifying an even 
higher-risk subgroup. (Svirsky et al., 2014; Ohkuchi et al., 2017; Townsend & Khalil, 2018)  
It has been proved that, maybe due to the larger placental implantation size and the different 
hemodynamic maternal status, the mean uterine artery resistance is lower in twins than in singletons. 
(Yu et al., 2002; Klein et al., 2011; Geipel et al., 2011; Svirsky et al., 2014) Furthermore, there appears 
to be no significant difference in UtA-PI values between MC and DC pregnancies, which corroborates 
the current evidence that total placental size, rather than genetic or hormonal factors, is likely to play 
a central role in hemodynamic alterations related to implantation. (Yu et al., 2002; Klein et al., 2011; 
Rizzo et al., 2014)  
In twin pregnancies, UtA-PI is increased in the first trimester in pregnancies that develop early-onset 
PE but not significantly in the cases of late-onset PE. These findings are consistent with those found in 
singleton pregnancies, showing that uterine artery Doppler is more efficient in identifying women 
who develop severe early-onset PE rather than the late form of the disease. (Svirsky et al., 2014; Rizzo 
et al., 2014) If the reference ranges used in singleton are applied to twin pregnancies, a higher rate of 
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false negative can be anticipated. (Papageorghiou et al., 2001; Sebire, 2002; Geipel et al., 2002) In 
recent studies the performance of uterine Doppler in the prediction of PE was slightly poorer for 
twins than for singletons. The application of twin reference curves results in sensitivity around 35% 
(for a screen-positive rates of 5%) and negative predictive values close to 95%. Despite the lower 
sensitivity, given the incidence of PE in twin pregnancies is higher than in singletons, the positive 
predictive value for this condition in twins is higher than in singletons. (Yu et al., 2002; Klein et al., 
2011)  
Biochemistry markers 
Numerous findings support the hypothesis that an angiogenic imbalance is present in women that 
develop PE. Particularly, levels of the anti-angiogenic protein s-Flt1 are high and levels of pro-
angiogenic proteins, such as PlGF are low in pregnancies with PE. (Maynard et al., 2003; Levine et al., 
2004; Kusanovic et al., 2009; Chaiworapongsa et al., 2011)  
When comparing singleton and twin pregnancies, studies demonstrated higher levels of PlGF, sFlt-1 
and higher sFlt-1/PlGF ratio in twins. (Rana et al., 2012a; Dröge et al., 2015)  
In twins with PE versus unaffected pregnancies, the serum levels of sFlt-1 and the sFlt-1/PlGF-ratio 
are significantly increased and PlGF is significantly decreased. (Bdolah et al., 2008; Rana et al., 2012b; 
Dröge et al., 2015; Svirsky et al., 2016) The deviations of these angiogenic markers appear to predict 
adverse outcomes, and the sFlt-1/PlGF-ratio is inversed correlated with the duration of pregnancy. 
These results are comparable to those found in singleton pregnancy. (Rana et al., 2012a; Rana et al., 
2012b) 
Another biochemistry marker assessed was PAPP-A. When comparing unaffected pregnancies, PAPP-
A was significantly higher in twins versus singletons. In pregnancies complicated by PE the median 
PAPP-A level was significantly raised in twins, in contrast to what happens in singleton pregnancies. 
(Svirsky et al., 2016) One possible justification for the increased PAPP-A levels in twin pregnancies 
with PE is placental over-compensation. This could happen if, due to impaired blood flow in one 
placenta, blood flow is increased in the other placenta in order to compensate it but without 
adequate control.  (Svirsky et al., 2016) 
Screening algorithm 
Similarly to aneuploidies, the most effective screening tool for PE in singleton pregnancies is achieved 
with a combined model. (O’Gorman et al., 2016) (O’Gorman et al., 2017) In these reports twin 
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pregnancies were excluded. 
An earlier study aimed to create an effectively tool to predict PE in twins. (Maymon et al., 2017) The 
algorithm developed, combining maternal factors, biophysical (MAP and UtA-PI) and biochemistry 
markers (PAPP-A, PlGF and placental protein 13- PP13) reported a detection rate (DR) of 75% for a 
false positive rate (FPR) of 10%.  The major limitations of this research are the small size of the cohort 
(n=105), the use of a contingent approach, with biomarkers being assessed in the first and second 
trimester and the introduction of a new marker (PP13) not routinely used in screening, which adds 
additional cost.  
PREVENTION  
Bearing in mind that the pathophysiology of PE is not fully understood, the search for a preventive 
strategy remains an unfulfilled goal. Many approaches to prevent PE have been studied, but only the 
use of low-dose dose aspirin has been found to be effective. (August, 2017; Norwitz, 2017) 
In singletons pregnancies if screening is carried out before 16 weeks of pregnancy, the daily 
administration of a low-dose dose aspirin in the high-risk patient reduces the incidence of PE.  
According to the most recent studies a 10-fold reduction in the incidence of early-onset PE is 
expected. (Bujold et al., 2010; Roberge et al., 2012; Rolnik et al., 2017)  
Similar to what happens in singletons, the identification during the first trimester of twin pregnancies 
at higher risk of developing PE could form the basis of prophylactic treatments started early in 
pregnancy. There is little data about the use of aspirin in multiple pregnancies. (Caspi et al., 1994; 
Euser et al., 2016) There are some health organizations that support the routine use of low-dose 
aspirin in all twin pregnancies to prevent PE. (WHO, 2011; U.S. Preventative Services Task Force, 
2014) Nonetheless, if the adverse effects and compliance are considered, possibly not every twin 
pregnancy should receive aspirin. Screening strategies intended to select higher-risk twin pregnancies 
would be preferable to indiscriminate use.  
 
 
 
INTRODUCTION 
35 
 
Despite the extensive research publications in relation to PE in twins there are still several 
unanswered questions. One important problem is determining how high is the relative risk of PE in 
twins compared with singletons and what is the significance of the other risk factors for PE in twins.  
Furthermore is important to clarify the influence of the maternal characteristics and medical history 
in the risk of PE in twin pregnancy. It is also fundamental to determine the specific profile of different 
biomarkers in twins with PE and with unaffected pregnancies. These are the essential steps to create 
an effective algorithm to screen for PE, allowing the identification of an even high-risk group of twins 
that could benefit from more intensive surveillance and prophylactic measures. 
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AIMS OF THE THESIS 
 
The aims of the studies in this thesis are: 
 
1. To determine the relative risk for total and preterm-PE in twin pregnancies when compared with 
singleton pregnancies. 
 
2. To access the influence of maternal characteristics and medical history in the prediction of PE in 
twin pregnancies. 
 
3. To develop a model for the prediction of PE by a combination of maternal factors and biomarkers 
in twin pregnancies.  
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This thesis involves three prospective studies for PE. The data were collected from twin pregnancies 
undergoing first-trimester combined screening for aneuploidy between January 2006 and December 
2015 and subsequently delivering two phenotypically normal live or stillborn babies at or after 24 
weeks’ gestation. Data on pregnancy outcome were collected and the obstetric records of all women 
with pre-existing or pregnancy-associated hypertension were examined to determine if the condition 
was PE, as defined by the International Society for the Study of Hypertension in Pregnancy. The study 
population included 1789 DC and 430 MC twin pregnancies. For comparison of data, a convenience 
cohort of 93297 singleton pregnancies that were examined in the same hospitals was analysed. 
STUDY 1 
The objective of this first study was to determine the gestational age at delivery in DC and MC twin 
pregnancies, with and without PE, and calculate the relative risk for total and preterm-PE compared 
to singleton pregnancies.  
The distribution of gestational age at delivery of DC and MC twins was compared to singleton 
pregnancies from the same hospitals. The relative risk for total and preterm-PE in twins compared to 
singleton pregnancies was assessed. Kaplan Meier estimates of the cumulative incidence of PE in twin 
and singleton pregnancies, assuming no other cause for delivery, were determined and hazard ratios 
for twins relative to singletons were obtained from a Cox proportional hazards regression model.  
Median gestational age at delivery was 40.0 weeks for singletons, 37.0 weeks for DC twins and 35.4 
weeks for MC twins. The rate of PE in singletons was 2.3% (2162 of 93297), in DC twin pregnancies it 
was 8.1% (145 of 1789) and in MC twins it was 6.0% (26 of 430). Compared to singletons, the relative 
risk of total PE was 3.5 for DC twins and 2.6 for MC twins. Delivery before 37 weeks’ gestation 
occurred in 5.5% of singletons, in 46.5% of DC twins and in 91.4% of MC twins. The rate of preterm-PE 
was 0.6%, 5.5%, 5.8% for singletons, DC twins and MC twins, respectively. Compared to singletons, 
the relative risk of preterm-PE was 8.7 for DC twins and 9.1 for MC twins. In the Cox proportional 
hazards model the hazard ratios for DC and MC twin pregnancies relative to singleton pregnancies 
were 14 and 23, respectively.  
Our results showed that the relative risk for preterm-PE in DC and MC twins is similar and they are 
both substantially higher than in singleton pregnancies. In ongoing pregnancies the relative risk of PE 
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in the subsequent few days is much higher in twin than singleton pregnancies and thus the former 
may merit a closer monitoring.  
STUDY 2 
The objective of this study was to develop a survival-time regression model for the gestational age at 
delivery in DC and MC twin pregnancies with PE, using maternal demographic characteristics and 
medical history. The risk of PE with delivery before 37 and before 42 weeks’ gestation in twin 
pregnancies was assessed and compared to singleton pregnancies. 
A previous study showed that in singleton pregnancies the mean of the Gaussian distribution of 
gestational age for delivery with PE for a reference population (Caucasian, weight of 69 kg at 12 
weeks’ gestation, height of 164 cm, nulliparous, with spontaneous conception, no family history of PE 
and no history of diabetes mellitus, systemic lupus erythematosus or antiphospholipid syndrome) is 
55 weeks. (Wright et al., 2012) In DC twins with PE, the mean gestational age at delivery was shifted 
to the left by 8.2 (95% CI 7.2-9.1) weeks and in MC twins it was shifted to the left by 10.0 (95% CI 8.5-
11.4) weeks. The estimated risk of PE before 37 weeks’ gestation, assuming no other cause of 
delivery, was 0.6% for singletons, 9.0% for DC twins and 14.2% for MC twins; the respective values for 
PE before 42 weeks were 3.6%, 27.0% and 36.5%.  Screening for PE in twins, using maternal 
demographic characteristics and medical history, has a high DR but at the cost of a very high screen 
positive rate (SPR). At all risk cut-offs the screen-positive rate was much higher for twin than singleton 
pregnancies and, at a risk cut-off of 1 in 75, nearly all twin pregnancies were screened positive.  
In conclusion, a model based on maternal characteristics and history has been developed for 
estimation of patient-specific risks for PE in DC and MC twin pregnancies. Such estimation of the a 
priori risk for PE is an essential first step in the use of Bayes theorem to combine maternal factors 
with biomarkers for the continuing development of more effective methods of screening for the 
disease. 
STUDY 3 
The objective of this study was to develop a model for screening for PE in twin pregnancies based on 
maternal demographic characteristics, medical history and biomarkers at 11-13 weeks’ gestation. 
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In this study only patients with complete data on biophysical and biochemistry markers were 
included. The study population involved 1100 twin pregnancies and, for comparison of data, results 
from 35948 singleton pregnancies that were examined in the same hospitals were used. Bayes 
theorem was used to combine the a priori risk from maternal factors with various combinations of 
UtA-PI, MAP, PAPP-A and PlGF converted in MoM values. The performance of screening for PE 
requiring delivery before 32, 37 and 42 weeks’ gestation was estimated. 
In twin pregnancies that developed PE, the values of MAP and UtA-PI were increased and PlGF and 
PAPP-A were decreased. The distributions of MoM values of biomarkers with gestational age at 
delivery were similar to those that were previously reported in singleton pregnancies and it was 
therefore assumed that the same model can be used for both singleton and twin pregnancies. The 
performance of screening for PE by maternal factors was improved by the addition of MAP, UtA-PI 
and PlGF; there was no further improvement with the addition of PAPP-A. In a mixed population of 
singleton and twin pregnancies, combined screening by maternal factors, MAP, UtA-PI and PlGF and 
risk cut-off of 1 in 75 for PE before 37 weeks, the detection rate of PE before 32, 37 and 42 weeks in 
singleton pregnancies was 91%, 77% and 57%, respectively, at SPR of 13%; the respective rates for 
twin pregnancies were 100%, 99% and 97%, at SPR of 75%.  
It was concluded that first-trimester combined screening for PE in singleton pregnancies can be 
adapted for screening in twins leading to detection of nearly all affected cases but at a high SPR. 
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PRINCIPAL FINDINGS AND COMPARISON WITH PREVIOUS STUDIES 
The results of our first study showed that in twin pregnancies, compared to singleton pregnancies, 
the overall rate of PE is about 3 times higher, consistent with the results of previous reports. 
(Savvidou et al., 2001; Yu et al., 2002; Geipel et al., 2002; Klein et al., 2011; Sparks et al., 2013; Rizzo 
et al., 2014; Bensdorp et al., 2016; Lučovnik et al., 2016; Wang et al., 2016; Barda et al., 2017) We also 
found that the rate of PE for DC and MC twins is similar. This is also compatible with the results of other 
studies. (Savvidou et al., 2001; Yu et al., 2002; Klein et al., 2011; Rizzo et al., 2014; Lučovnik et al., 
2016)  
Additionally, our findings revealed that in twin pregnancies the rate of preterm-PE, between 24+0 
and 36+6 weeks’ gestation, is nine times higher than in singletons. In fact, if we consider the risk for 
preterm-PE in the subgroup of pregnancies that are ongoing at 35 weeks’ gestation the relative risk is 
14 for DC twins and 20 for MC twins and these rates were very similar to the hazard ratios of 14 for 
DC and 23 for MC twin pregnancies relative to singleton pregnancies.  
The underestimate relative risk of PE in twins, by comparison with singletons, when reporting the 
total rate of PE from 24 to 42 weeks’ gestation is a mere consequence of the lower gestational age at 
delivery in twin pregnancy. In our study the median gestational age at delivery was 40 weeks for 
singletons, 37 weeks for DC twins and 35 weeks for MC twins. Delivery before 37 weeks’ gestation 
occurred in 6% of singletons, 47% of DC twins and 91% of MC twins. These rates are similar to those 
reported for all births in the USA in 2014, where the rate of delivery before 37 weeks was 8% for 
singletons and 59% for twins. (Therneau, 2015) Since a much higher proportion of twin compared to 
singleton pregnancies deliver before a given gestational age, in the ongoing pregnancies the relative 
risk of PE in the subsequent few days is much higher than the value of 3 implied from the overall rate 
of PE. The true relative risk is about 14 for DC twins and more than 20 for MC twins.  
The adoption of a survival-time model for the gestational age at delivery with PE has previously been 
proposed. (Wright et al., 2012; Wright et al., 2015) This approach assumes that if the pregnancy was 
to continue indefinitely all women would develop PE. Whether they do so or not before a specified 
gestational age depends on competition between delivery before or after development of PE. It is 
therefore likely that if the pregnancy in twins was as long as in singletons the overall rate of PE in 
twins would be considerably higher than observed. 
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Former studies established a competing risk model for the prediction of PE in singleton pregnancies 
based on maternal factors. (Wright et al., 2012; Akolekar et al., 2013; Wright et al., 2015; O’Gorman 
et al., 2016; O’Gorman et al., 2017) In our second study, the maternal factor based model has been 
extended to include twin pregnancies.  
We confirmed that in twin pregnancies the risk of PE is substantially higher than in singleton 
pregnancies and this is reflected in the distribution of gestational age of delivery with PE. In a reference 
population (Caucasian women, weight of 69 kg, height of 164 cm, nulliparous, with spontaneous 
conception, no family history of PE and no history of diabetes mellitus, systemic lupus erythematosus or 
antiphospholipid syndrome), the mean gestational age of delivery with PE is 55 weeks. In DC and MC 
twin pregnancies with the same characteristics the distribution of gestational age of delivery with PE is 
shifted to the left by 8 and 10 weeks, respectively. The estimated risk of PE before 37 weeks’ gestation 
was 0.6% for singletons, 9.0% for DC twins and 14.2% for MC twins. 
In screening for PE before 37 weeks’ gestation at a risk cut-off of 1 in 75, in a mixed population of 
singleton and twin pregnancies, using maternal demographic characteristics and medical history, when 
the SPR for singleton pregnancies was 13% virtually all twins were screened positive. This is not 
surprising because in any screening programme certain maternal characteristics may be associated with 
such high-risk that irrespective of how favourable all other factors are, the posterior risk is above a cut-
off used for stratification of the population into high and low-risk groups. For example, in the context of 
first-trimester combined screening for trisomy 21, the prior risk increases exponentially with maternal 
age and for a woman aged 50 years the posterior risk will remain above the screen positive cut-off, 
irrespective of how favourable the measurements of fetal nuchal translucency thickness and serum free 
ß-hCG (human Chorionic Gonadotropin) and PAPP-A are. As far as we known, this is the first study were 
the maternal factor based model has been extended to include twin pregnancies. 
In our last study the competing risk model for the prediction of PE in twin pregnancies based on 
maternal factors has been extended to include biomarkers.  
Previous studies on uterine artery Doppler during the second and third trimesters reported that UtA-
PI in twin pregnancies is significantly lower than in singleton pregnancies, but the value is increased in 
pregnancies that develop PE. (Yu et al., 2002; Geipel et al., 2002; Geipel et al., 2011; Klein et al., 2011) 
A study in 421 twins and 500 singleton pregnancies at 11-13 weeks’ gestation measured UtA-PI and 
converted the values to MoM after correction for maternal body mass index, ethnicity and 
DISCUSSION  
77 
gestational age. (Rizzo et al., 2014) First, the study reported that median UtA-PI MoM was similar 
between MC and DC twins. Second they showed that UtA-PI in twins was lower than in singletons and 
third, in twin pregnancies that developed PE before 34 weeks’ gestation, but not in those with PE at 
or after 34 weeks, UtA-PI was increased. (Rizzo et al., 2014) Another first-trimester study in 147 twin 
and 110 singleton pregnancies assessed UtA-PI and converted the values to MoM after correction for 
maternal weight and gestational age. (Svirsky et al., 2014) The study reported that first, UtA-PI in 
twins was lower than in singletons, second, UtA-PI was higher in MC than DC twins and third, in 12 
twins that developed PE median UtA-PI was significantly lower. (Svirsky et al., 2014) This study also 
measured MAP and converted the values to MoM after correction for maternal weight and 
gestational age. They determined that first, MAP in twins was not significantly different from that in 
singletons, second, MAP was unrelated to chorionicity and third, in the twin pregnancies that 
developed PE median MAP was higher. (Svirsky et al., 2014) 
A study in 144 twin and 109 singleton pregnancies at 11-13 weeks’ gestation measured serum PAPP-A 
and PlGF and converted the values to MoM. (Svirsky et al., 2016)  They reported that first, in twin 
pregnancies PAPP-A and PlGF were approximately twice as high compared to singletons, and second, 
in the 12 twin pregnancies that developed PE PlGF values were decreased but PAPP-A was increased. 
(Svirsky et al., 2016)  A study in 74 twin and triplet pregnancies and 698 singleton pregnancies 
measured serum PlGF at 12-18 weeks’ gestation and showed that first, in multiple pregnancies the 
levels were higher than in singletons and second, in the 5 multiple pregnancies that developed PE 
PlGF was lower. (Boucoiran et al., 2013)  
In our study, DC twin pregnancies that did not develop PE, compared to singleton pregnancies, UtA-PI 
was lower, PlGF was higher and MAP was not significantly different. In MC twins, UtA-PI was lower, 
MAP was higher and PlGF was not significantly different. A previous study found that at 11-13 weeks’ 
gestation the estimated median MoM of PAPP-A was about 2.0 for DC twins and 1.6 for MC twins. 
(Madsen et al., 2011)   
In twin pregnancies that developed PE, MAP and UtA-PI at 11-13 weeks’ gestation were increased and 
serum PlGF was decreased. The distribution of biomarkers with gestational age at delivery was similar 
to the previously reported fitted regression relationships for singleton pregnancies with PE 
(O’Gorman et al., 2016) and it was therefore assumed that the same model can be used for both 
singleton and twin pregnancies. We propose an initial model using a twin specific prior risk with 
biomarker MoM values adjusted for twins, but singleton distributional parameters for biomarkers. 
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The results obtained using this model are marginally worse than using twin specific parameters. 
However, this may be the consequence of the optimistic bias introduced from fitting and testing on 
the same data.  
The performance of screening for PE by maternal factors was improved by the addition of MAP, UtA-
PI and PlGF. In screening for PE using a combined test in a mixed population of singleton and twin 
pregnancies, at a risk cut-off of 1 in 75, the estimated DR and SPR of preterm PE for singletons were 
77% and 13%, respectively, and the values for twins were 99% and 75%. If we use the risk cut-off of 1 
in 10 for twins, the DR of preterm PE and PE before 32 weeks is 69% and 100%, respectively, at an 
estimated SPR of 25%. 
STRENGTHS AND LIMITATIONS  
The major strength of our studies is the prospective examination of twin and singleton pregnancies 
attending for routine care, with identification of known factors associated with PE early in pregnancy. 
The assessment of pregnancies at this stage is already widely used to determine gestational age, 
chorionicity, diagnosis of major fetal defects and screening for trisomies. 
One other strong point is the fact that in study 1 the gestational age at delivery was taken into 
consideration and that the rate of preterm-PE was analysed instead of just the overall incidence of PE. 
In both studies 1 and 2 we used a survival-time model, which allows estimation of an individual patient-
specific risk of PE requiring delivery before any specified gestation. In study 2 and 3, the application of a 
multivariable survival analysis to identify the factors and define their contribution in the prediction of PE 
was also a central point of the investigation. In study 3, the use of a specific methodology and 
appropriately trained doctors to measure UtA-PI and MAP combined with the utilization of 
automated machines to provide accurate measurement within 40 minutes of sampling of maternal 
serum concentration of PlGF and PAPP-A were vital. The expression of the values of the biomarkers as 
MoMs and the use of Bayes theorem to combine the a priori risk from maternal factors with 
biomarkers, to estimate patient-specific risks, are also essential features of the study. The final 
strength of this research is the possibility to assess the performance of screening for PE at different 
stages of pregnancy.  
Overall, the major limitation of the studies is the inevitably small number of twin pregnancies examined 
relative to singleton ones. In the last two studies we adopted the pragmatic view of using the model 
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that was previously described for singleton pregnancies to examine both singleton and twin 
pregnancies. This model requires validation and possible adjustments from the study of larger 
datasets of twins. Additionally, both studies have the limitation of the performance of screening by a 
model derived and tested using the same dataset being overestimated. We believe, external validation 
on independent data from different sources is required.   
CLINICAL IMPLICATIONS  
Clinicians managing twin pregnancies should be aware that the rate of preterm-PE, relative to that in 
singleton pregnancies, is substantially higher than what is implied by the overall rate of PE. They 
should also be attentive that, during the third trimester in ongoing pregnancies, the relative risk of PE 
in the subsequent few days is much higher in twin than singleton pregnancies which should merit a 
higher intensity of monitoring for PE.  
The proposed competing risk model allows an estimation of patient-specific a priori risk for PE in twins, 
which is an essential first step in the use of Bayes theorem to combine maternal factors with biomarkers 
and for the continuing development of more effective methods of screening. Bayes theorem also 
provides a framework for updating the risk at different stages during pregnancy, forming the basis for 
stratified surveillance policies as achieved for singleton pregnancies.  
The same model of screening can be adapted and used in mixed populations of singleton and twin 
pregnancies. More studies, with independent data from different sources, are required to validate 
this model. 
FINAL REMARKS  
PE is one of the most common medical complications of pregnancy and is a major cause of maternal 
and perinatal morbidity and mortality. Nevertheless, its physiopathology is still enfolded in plenty of 
uncertainty, which generates several unanswered questions. 
Obstetricians face a growing number of multiple pregnancies, which have an increased risk of PE. 
Therefore, PE in twin pregnancies is a pertinent obstetric problem of increasing importance, requiring 
more research to elucidate the particularities of this pathology. 
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The aim of this thesis was to clarify some of the issues of PE in twin pregnancy. The studies enclosed 
can be the starting point of more research required to determine the best approach in screening for 
PE in twin pregnancy. One fundamental question that still needs to be addressed is whether there are 
effective prophylactic measures in twin pregnancy and what those are. One other important issue is 
whether it is more cost-effective to screen these pregnancies or to offer prophylactic measures 
universally. If screening is the way forward, it is imperative to improve the used screening method. 
Given all the above, this is definitely an area that deserves further attention by the Obstetric 
community. 
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